Drug Profile
SDZ 280636
Alternative Names: MDP-threo-GDPLatest Information Update: 20 Jun 2001
Price :
$50
*
At a glance
- Originator Novartis
- Class Antiallergics; Dipeptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypersensitivity
Most Recent Events
- 20 Jun 2001 No-Development-Reported for Allergy in Austria (Unknown route)
- 07 Nov 1997 Preclinical development for Allergy in Austria (Unknown route)